CN114555565A - 含氮并环化合物、其制备方法及用途 - Google Patents

含氮并环化合物、其制备方法及用途 Download PDF

Info

Publication number
CN114555565A
CN114555565A CN202080071984.6A CN202080071984A CN114555565A CN 114555565 A CN114555565 A CN 114555565A CN 202080071984 A CN202080071984 A CN 202080071984A CN 114555565 A CN114555565 A CN 114555565A
Authority
CN
China
Prior art keywords
compound
membered
radical
cycloalkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080071984.6A
Other languages
English (en)
Other versions
CN114555565B (zh
Inventor
游泽金
何云
李桂英
田强
宋宏梅
薛彤彤
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN114555565A publication Critical patent/CN114555565A/zh
Application granted granted Critical
Publication of CN114555565B publication Critical patent/CN114555565B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及含氮并环化合物、其制备方法及用途。具体而言，本发明涉及具有式X所示结构的化合物，所述化合物的立体异构体、互变异构体或其混合物，所述化合物的药学上可接受的盐、共晶、多晶型物或溶剂合物，或者所述化合物的稳定同位素衍生物、代谢物或前药。本发明的化合物可以具有式I或式III所示结构。这些化合物可用于细胞增殖异常性疾病(例如癌症)的治疗。R‑L‑R3式X

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN202080071984.6A 2019-12-13 2020-07-31 含氮并环化合物、其制备方法及用途 Active CN114555565B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911279540 2019-12-13
CN2019112795407 2019-12-13
PCT/CN2020/106220 WO2021114691A1 (zh) 2019-12-13 2020-07-31 含氮并环化合物、其制备方法及用途

Publications (2)

Publication Number Publication Date
CN114555565A true CN114555565A (zh) 2022-05-27
CN114555565B CN114555565B (zh) 2024-03-05

Family

ID=76329456

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080071984.6A Active CN114555565B (zh) 2019-12-13 2020-07-31 含氮并环化合物、其制备方法及用途

Country Status (2)

Country Link
CN (1) CN114555565B (zh)
WO (1) WO2021114691A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269753A (zh) * 2019-09-29 2022-04-01 四川科伦博泰生物医药股份有限公司 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1724268A1 (en) * 2004-02-20 2006-11-22 Kirin Beer Kabushiki Kaisha Compound having tgf-beta inhibitory activity and pharmaceutical composition containing same
CN101056865A (zh) * 2004-11-09 2007-10-17 霍夫曼-拉罗奇有限公司 氨基喹唑啉化合物
CN104582703A (zh) * 2012-06-08 2015-04-29 森索睿翁公司 用于治疗耳鸣的h4受体抑制剂
WO2019166532A1 (en) * 2018-03-01 2019-09-06 Janssen Sciences Ireland Unlimited Company 2,4-diaminoquinazoline derivatives and medical uses thereof
WO2019214546A1 (zh) * 2018-05-11 2019-11-14 四川科伦博泰生物医药股份有限公司 稠环化合物、其制备方法及用途
CN113301963A (zh) * 2019-01-14 2021-08-24 先天肿瘤免疫公司 用于治疗癌症的作为nlrp3调节剂的取代的喹唑啉类

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2270002A1 (en) * 2009-06-18 2011-01-05 Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg Quinazoline derivatives as histamine H4-receptor inhibitors for use in the treatment of inflammatory disorders
WO2018021977A1 (en) * 2016-07-29 2018-02-01 Agency For Science, Technology And Research Glycine metabolism modulators and uses thereof
BR112020000523A2 (pt) * 2017-07-14 2020-07-14 Innate Tumor Immunity, Inc. moduladores de nlrp3

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1724268A1 (en) * 2004-02-20 2006-11-22 Kirin Beer Kabushiki Kaisha Compound having tgf-beta inhibitory activity and pharmaceutical composition containing same
CN101056865A (zh) * 2004-11-09 2007-10-17 霍夫曼-拉罗奇有限公司 氨基喹唑啉化合物
CN104582703A (zh) * 2012-06-08 2015-04-29 森索睿翁公司 用于治疗耳鸣的h4受体抑制剂
WO2019166532A1 (en) * 2018-03-01 2019-09-06 Janssen Sciences Ireland Unlimited Company 2,4-diaminoquinazoline derivatives and medical uses thereof
WO2019214546A1 (zh) * 2018-05-11 2019-11-14 四川科伦博泰生物医药股份有限公司 稠环化合物、其制备方法及用途
CN113301963A (zh) * 2019-01-14 2021-08-24 先天肿瘤免疫公司 用于治疗癌症的作为nlrp3调节剂的取代的喹唑啉类

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"REGISTRY[online]", 《STN检索报告REGISTRY》, pages 1 - 3 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269753A (zh) * 2019-09-29 2022-04-01 四川科伦博泰生物医药股份有限公司 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途
CN114269753B (zh) * 2019-09-29 2024-03-05 四川科伦博泰生物医药股份有限公司 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途

Also Published As

Publication number Publication date
CN114555565B (zh) 2024-03-05
WO2021114691A1 (zh) 2021-06-17

Similar Documents

Publication Publication Date Title
EP3402799B1 (en) Heterocyclic compounds as rsv inhibitors
AU2016317521B2 (en) Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof
KR101879422B1 (ko) Btk 및/또는 jak3 키나제의 활성을 억제하는 화합물
KR101982912B1 (ko) 융합된 헤테로사이클릭 화합물, 이의 제조 방법, 약학적 조성물, 및 그 용도
TW201811795A (zh) 胺基－吡咯并嘧啶酮化合物及其用途
WO2019094920A1 (en) Azepin-2-one derivatives as rsv inhibitors
CN113195469A (zh) 含氮并环化合物、其制备方法及用途
EP2945623A1 (en) Hedgehog pathway signaling inhibitors and therapeutic applications thereof
US20230265116A1 (en) Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use
WO2018218042A1 (en) Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
TW202016120A (zh) 含三并環類衍生物抑制劑、其製備方法和應用
UA121925C2 (uk) 1,5-ДИГІДРО-4H-ПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНИ ТА 1,5-ДИГІДРО-4H-ПІРАЗОЛО[4,3-c]ПІРИДИН-4-ОНИ ЯК ІНГІБІТОРИ PDE1
JP2021522279A (ja) アポトーシスシグナル調節キナーゼ１阻害剤を含むテトラゾール及びその使用方法
CN112654622B (zh) 并环化合物、其制备方法及用途
JP2022523477A (ja) ピロロピリミジン誘導体及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防又は治療用薬学的組成物
EP3939979A1 (en) Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine
CN107743491B (zh) 用于治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物
CN113330009A (zh) 氮杂环化合物、其制备方法及用途
CN114555565B (zh) 含氮并环化合物、其制备方法及用途
US20220259210A1 (en) Pyrazolone-Fused Pyrimidine Compound, Preparation Method for Same and Applications Thereof
CN111377873B (zh) 氨基嘧啶化合物及其制备方法和用途
AU2018337138B2 (en) 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof
CN114269753B (zh) 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途
CN111253390B (zh) 并环化合物、其制备方法及用途
EP4219453A1 (en) Pyrazole compound and preparation method therefor and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant